NBSE Stock Overview
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
NeuBase Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.03|
|52 Week High||US$5.51|
|52 Week Low||US$0.89|
|1 Month Change||-36.81%|
|3 Month Change||-28.97%|
|1 Year Change||-80.23%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-77.36%|
Recent News & Updates
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|NBSE||US Biotechs||US Market|
Return vs Industry: NBSE underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: NBSE underperformed the US Market which returned -10.8% over the past year.
|NBSE Average Weekly Movement||12.0%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: NBSE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NBSE's weekly volatility (12%) has been stable over the past year.
About the Company
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington’s disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene.
NeuBase Therapeutics Fundamentals Summary
|NBSE fundamental statistics|
Is NBSE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NBSE income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.04|
|Net Profit Margin||0.00%|
How did NBSE perform over the long term?See historical performance and comparison
Is NeuBase Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NBSE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NBSE's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NBSE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: NBSE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NBSE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NBSE is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (1.4x).
How is NeuBase Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NBSE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NBSE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NBSE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NBSE is forecast to have no revenue next year.
High Growth Revenue: NBSE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NBSE's Return on Equity is forecast to be high in 3 years time
How has NeuBase Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NBSE is currently unprofitable.
Growing Profit Margin: NBSE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NBSE is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare NBSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NBSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: NBSE has a negative Return on Equity (-87.71%), as it is currently unprofitable.
How is NeuBase Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NBSE's short term assets ($40.2M) exceed its short term liabilities ($5.0M).
Long Term Liabilities: NBSE's short term assets ($40.2M) exceed its long term liabilities ($5.7M).
Debt to Equity History and Analysis
Debt Level: NBSE is debt free.
Reducing Debt: NBSE had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NBSE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NBSE has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 60% each year.
What is NeuBase Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NBSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NBSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NBSE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NBSE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NBSE has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dietrich Stephan (51 yo)
Dr. Dietrich A. Stephan, Ph D., is the Founder of Silicon Valley Biosystems, Inc., and serves as its Chief Executive Officer and President. Dr. Stephan serves as Scientist in Chief and Founding Member at L...
CEO Compensation Analysis
Compensation vs Market: Dietrich's total compensation ($USD1.51M) is above average for companies of similar size in the US market ($USD772.03K).
Compensation vs Earnings: Dietrich's compensation has increased whilst the company is unprofitable.
Experienced Management: NBSE's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: NBSE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NBSE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
NeuBase Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: NeuBase Therapeutics, Inc.
- Ticker: NBSE
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$30.968m
- Shares outstanding: 32.26m
- Website: https://www.neubasetherapeutics.com
Number of Employees
- NeuBase Therapeutics, Inc.
- 350 Technology Drive
- Third Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.